{"type":"trials","record":{"id":41964,"source_id":"clinicaltrials-gov","external_id":"NCT03630315","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","brief_summary":"To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Ocular Therapeutix, Inc.","enrollment":29,"countries":["Australia"],"start_date":"2019-02-18","completion_date":"2024-01-10","last_update_date":"2024-07-10","source_url":"https://clinicaltrials.gov/study/NCT03630315","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 100 Years","comparator":null,"organization":"Ocular Therapeutix, Inc.","interventions":["OTX-TKI","Anti-VEGF"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence of treatment emergent adverse events for each subject — 9 months","Determine the Maximum Tolerated Dose of the OTX-TKI injection — 9 months"],"design_description":"RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","OTX-TKI","Anti-VEGF"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03630315","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-02-18 to 2024-01-10","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 100 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.900Z","intervention":["OTX-TKI","Anti-VEGF"],"participants":29,"study_design":"RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence of treatment emergent adverse events for each subject — 9 months","Determine the Maximum Tolerated Dose of the OTX-TKI injection — 9 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41964","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}